Cargando…

Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?

Genetic and epigenetic factors have an important role during the development of osteoporosis. Receptor activator of nuclear factor-κ B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL) pathway is important for the bone remodeling, and NFATC1 and FOS are the downtargets of this pathway. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalkan, R, Tosun, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009562/
https://www.ncbi.nlm.nih.gov/pubmed/33816070
http://dx.doi.org/10.2478/bjmg-2020-0021
_version_ 1783672899346890752
author Kalkan, R
Tosun, O
author_facet Kalkan, R
Tosun, O
author_sort Kalkan, R
collection PubMed
description Genetic and epigenetic factors have an important role during the development of osteoporosis. Receptor activator of nuclear factor-κ B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL) pathway is important for the bone remodeling, and NFATC1 and FOS are the downtargets of this pathway. Here, we report methylation status of NFATC1 and FOS genes in post- and premenopausal women. In this study, 30 premenopausal and 35 postmenopausal women were included. Methylation sensitive-high resolution melting (MS-HRM) analysis was used for identification of NFATC1 and FOS genes methylation. The NFATC1 gene was methylated in 11 of the 35 postmenopausal women, and the FOS gene was methylated in six of the postmenopausal women (p >0.005). Here, we found statistically significant association between unmethylation of the NFATC1 gene and postmenopausal status. This result explains the epigenetic regulation of osteoclasts during the menopausal transition, and for the first time, our results can be used for epigenetic explanation of postmenopausal osteoporosis in the literature. However, the limited number of studies in this field makes our results crucial. Our results showed great value of epigenetic profiles of postmenopausal women.
format Online
Article
Text
id pubmed-8009562
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-80095622021-04-02 Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis? Kalkan, R Tosun, O Balkan J Med Genet Original Article Genetic and epigenetic factors have an important role during the development of osteoporosis. Receptor activator of nuclear factor-κ B (NF-κB) (RANK)/receptor activator of NF-κB ligand (RANKL) pathway is important for the bone remodeling, and NFATC1 and FOS are the downtargets of this pathway. Here, we report methylation status of NFATC1 and FOS genes in post- and premenopausal women. In this study, 30 premenopausal and 35 postmenopausal women were included. Methylation sensitive-high resolution melting (MS-HRM) analysis was used for identification of NFATC1 and FOS genes methylation. The NFATC1 gene was methylated in 11 of the 35 postmenopausal women, and the FOS gene was methylated in six of the postmenopausal women (p >0.005). Here, we found statistically significant association between unmethylation of the NFATC1 gene and postmenopausal status. This result explains the epigenetic regulation of osteoclasts during the menopausal transition, and for the first time, our results can be used for epigenetic explanation of postmenopausal osteoporosis in the literature. However, the limited number of studies in this field makes our results crucial. Our results showed great value of epigenetic profiles of postmenopausal women. Sciendo 2021-03-23 /pmc/articles/PMC8009562/ /pubmed/33816070 http://dx.doi.org/10.2478/bjmg-2020-0021 Text en © 2020 Kalkan R, Tosun O, published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Original Article
Kalkan, R
Tosun, O
Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?
title Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?
title_full Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?
title_fullStr Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?
title_full_unstemmed Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?
title_short Do We Use Methylation of NFATC1 and FOS Genes As a Biomarker for Postmenopausal Osteoporosis?
title_sort do we use methylation of nfatc1 and fos genes as a biomarker for postmenopausal osteoporosis?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009562/
https://www.ncbi.nlm.nih.gov/pubmed/33816070
http://dx.doi.org/10.2478/bjmg-2020-0021
work_keys_str_mv AT kalkanr doweusemethylationofnfatc1andfosgenesasabiomarkerforpostmenopausalosteoporosis
AT tosuno doweusemethylationofnfatc1andfosgenesasabiomarkerforpostmenopausalosteoporosis